At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 71 enrolled
Drug / intervention
Rosiglitazone +1 moredrug
Likely dose
Rosiglitazone 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Placebo Controlled Study of Rosiglitazone in HIV Lipoatrophy
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 23, 2006·Updated Feb 6, 2017
In Brief
A Phase 2 clinical trial evaluating Rosiglitazone and Placebo for HIV Infections. Completed, enrolled 71 participants across 2 sites.
Detailed Summary
The purpose of this study is to examine the effect of rosiglitazone on limb fat and mitochondrial indices in HIV-1-infected subjects receiving stable antiretroviral therapy that does not contain stavudine (d4T) or zidovudine (AZT).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedAug 2006
Primary CompletionDec 2008
TodayJul 2026
First PostedAug 23, 2006
Enrollment StartJul 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 19.9 years ago
Interventions
Rosiglitazonedrug
Rosiglitazone 4mg BID
Placebodrug
Placebo for rosiglitazone